Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
Last updated: 2026-04-08 22:11:11 ET
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
A 59-year-old man lost 25 pounds on Foundayo, the new GLP-1 weight-loss pill
Also in Weekend Reads: The global energy market’s long road back after the Iran conflict ends, differences between new GLP-1 pills, and a simple 50/...
Police appeared to remove two pills from his pockets during a search.
Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s WegovyThe US Food and Drug Administration (FD...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE